Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma

作者：Jianwei Zhang, Tao Qin, Shao-Dong Hong, Jing Zhang, Wenfeng Fang, Yuanyuan Zhao, Yun-Peng Yang, Cong Xue, Yan Huang, Hongyuan Zhao, Yuxiang Ma, Zhi-Huang Hu, Pei‐Yu Huang, Li Zhang · 发表于：癌症：英文版 · 年份：2015 · DOI：10.1186/s40880-015-0011-0 · 被引用次数：14 · 研究领域：Head and Neck Cancer Studies、Cancer-related Molecular Pathways、Virus-based gene therapy research

INTRODUCTION: An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal carcinoma (NPC). However, targeted therapy-related oncogenic mutations have not been fully evaluated. This study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determine which targeted therapy might be potentially effective in treating NPC. METHODS: By using the SNaPshot assay, a rapid detection method, 19 mutation hotspots in 6 targeted therapy-related oncogenes were examined in 70 NPC patients. The associations between oncogenic mutations and clinicopathologic factors were analyzed. RESULTS: Among 70 patients, 12 (17.1%) had mutations in 5 oncogenes: 7 (10.0%) had v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) mutation, 2 (2.8%) had epidermal growth factor receptor (EGFR) mutation, 1 (1.4%) had phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation, 1 (1.4%) had Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and 1 (1.4%) had simultaneous EGFR and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations. No significant differences were observed between oncogenic mutations and clinicopathologic characteristics. Additionally, these oncogenic mutations were not associated with tumor recurrence and metastasis. CONCLUSIONS: Oncogenic mutations are present in NPC patients. The efficacy of targeted drugs on patients with the related oncogenic mutations requires further valida...